Condition (MeSH)
Hepatoblastoma
ClinicalTrials.gov lists 81 trials for Hepatoblastoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 16.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
81 of the 81 trials are tagged with Hepatoblastoma itself; the rest are tagged with a narrower condition beneath it.
When did Hepatoblastoma trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 5 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 7 |
| 2021 | 10 |
| 2020 | 5 |
| 2019 | 1 |
| 2018 | 8 |
| 2017 | 9 |
| 2016 | 2 |
Showing 10 of 27 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 56 months across 42 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hepatoblastoma trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 17 |
| Phase 1/2 | 6 |
| Phase 2 | 25 |
| Phase 2/3 | 2 |
| Phase 3 | 8 |
| Phase 4 | 1 |
| Not applicable | 4 |
| Observational | 16 |
| Expanded access | 2 |
How many Hepatoblastoma trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 16 |
| Active, not recruiting | 15 |
| Available | 1 |
| Completed | 30 |
| Suspended | 1 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hepatoblastoma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 16 |
| Children's Oncology Group | 9 |
Which drugs are being tested for Hepatoblastoma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Irinotecan | 5 |
| Cytoxan | 5 |
| Sodium Thiosulfate | 5 |
| Melphalan | 4 |
| OXALIPLATIN | 3 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 7 |
| Cisplatin 1 | 6 |
| Etoposid | 5 |
| Positron Emission Tomography (PET) | 4 |
| Bone scan | 4 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hepatoblastoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile neutropenia | 26 | 3 |
| Neutrophil count decreased | 25 | 5 |
| Platelet count decreased | 22 | 4 |
| Disease progression | 20 | 9 |
| Dehydration | 19 | 8 |
Showing 5 of 10 adverse events.
Which publications cover Hepatoblastoma? (27)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee. | Pediatric blood & cancer | 2023 | Yes |
| MRI-based deep learning model for differentiation of hepatic hemangioma and hepatoblastoma in early infancy. | European journal of pediatrics | 2023 | Yes |
| Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022 | Yes |
| Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. | The Lancet. Oncology | 2019 | Yes |
| Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. | The New England journal of medicine | 2018 | Yes |
Showing 5 of 27 publications.
Prevalence (69)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hepatoblastoma | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Unspecified |
| Hepatoblastoma | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Hepatoblastoma | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Hepatoblastoma | Annual incidence | <1 / 1 000 000 | Norway | Not stated | Exact |
| Hepatoblastoma | Annual incidence | <1 / 1 000 000 | Netherlands | Not stated | Exact |
Showing 5 of 69 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hepatoblastoma | 449 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Hepatoblastoma | 449 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.